Terns scores $80M in Se­ries B fi­nanc­ing led by Vi­vo, Or­biMed

Transpa­cif­ic biotech up­start Terns Phar­ma­ceu­ti­cals, which is fo­cused on de­vel­op­ing treat­ments for NASH and can­cer, has closed $80 mil­lion in Se­ries B fi­nanc­ing as it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER